254 related articles for article (PubMed ID: 2580934)
1. Inhibition of Epstein-Barr virus (EBV) release from the P3HR-1 Burkitt's lymphoma cell line by a monoclonal antibody against a 200,000 dalton EBV membrane antigen.
Sairenji T; Reisert PS; Spiro RC; Connolly T; Humphreys RE
J Exp Med; 1985 May; 161(5):1097-111. PubMed ID: 2580934
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Epstein-Barr virus (EBV) release from P3HR-1 and B95-8 cell lines by monoclonal antibodies to EBV membrane antigen gp350/220.
Sairenji T; Bertoni G; Medveczky MM; Medveczky PG; Nguyen QV; Humphreys RE
J Virol; 1988 Aug; 62(8):2614-21. PubMed ID: 2839689
[TBL] [Abstract][Full Text] [Related]
3. Immune response to intermediate filament-associated, Epstein-Barr virus-induced early antigen.
Sairenji T; Nguyen QV; Woda B; Humphreys RE
J Immunol; 1987 Apr; 138(8):2645-52. PubMed ID: 2435803
[TBL] [Abstract][Full Text] [Related]
4. Hybridization of a myeloid leukemia-derived human cell line (K562) with a human Burkitt's lymphoma line (P3HR-1).
Klein G; Zeuthen J; Eriksson I; Terasaki P; Bernoco M; Rosén A; Masucci G; Povey S; Ber R
J Natl Cancer Inst; 1980 Apr; 64(4):725-38. PubMed ID: 6245297
[TBL] [Abstract][Full Text] [Related]
5. Lysis of P3HR-1 cells induced to enter the viral cycle by antibody-dependent and independent immunological mechanisms.
Kurakata S; Ramos OF; Klein G; Klein E
Cell Immunol; 1989 Oct; 123(1):134-47. PubMed ID: 2550147
[TBL] [Abstract][Full Text] [Related]
6. p105, an Epstein-Barr virus-induced, phosphonoacetic acid-insensitive glycoprotein target of the anti-Epstein-Barr virus immune response.
Casareale D; Jones W; Sairenji T; Humphreys RE
Infect Immun; 1983 Jan; 39(1):85-90. PubMed ID: 6295961
[TBL] [Abstract][Full Text] [Related]
7. High Epstein-Barr virus (EBV) susceptibility of both lymphoblastoid and lymphoma cell lines derived from a Japanese patient with EBV genome-positive Burkitt's lymphoma.
Okano M; Aya T; Mizuno F; Takada K; Osato T
Tohoku J Exp Med; 1993 Jun; 170(2):71-9. PubMed ID: 8266328
[TBL] [Abstract][Full Text] [Related]
8. Persistence of transforming and nontransforming Epstein-Barr virus in high passages of P3HR-1 cell lines.
Gerber P; Ablashi D; Magrath I; Armstrong G; Andersen P; Trach L
J Natl Cancer Inst; 1982 Sep; 69(3):585-90. PubMed ID: 6287082
[TBL] [Abstract][Full Text] [Related]
9. Appearance of early and late components of Epstein-Barr virus-associated membrane antigen in Daudi cells superinfected with P3HR-1 virus.
Sairenji T; Hinuma Y; Sekizawa T; Yoshida M
J Gen Virol; 1978 Jan; 38(1):111-20. PubMed ID: 202665
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal antibody specific for capsid antigen of Epstein-Barr virus.
Takada K; Fujiwara S; Yano S; Osato T
Med Microbiol Immunol; 1983; 171(4):225-31. PubMed ID: 6304479
[TBL] [Abstract][Full Text] [Related]
11. Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein.
Qualtiere LF; Chase R; Vroman B; Pearson GR
Proc Natl Acad Sci U S A; 1982 Jan; 79(2):616-20. PubMed ID: 6176998
[TBL] [Abstract][Full Text] [Related]
12. Functional association of class II antigens with cell surface binding of Epstein-Barr virus.
Reisert PS; Spiro RC; Townsend PL; Stanford SA; Sairenji T; Humphreys RE
J Immunol; 1985 Jun; 134(6):3776-80. PubMed ID: 2985696
[TBL] [Abstract][Full Text] [Related]
13. Transient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.
Fresen KO; zur Hausen H
Proc Natl Acad Sci U S A; 1977 Jan; 74(1):363-6. PubMed ID: 189313
[TBL] [Abstract][Full Text] [Related]
14. Re-evaluation of a transforming strain of Epstein-Barr virus from the Burkitt lymphoma cell line, Jijoye.
Sairenji T; Hinuma Y
Int J Cancer; 1980 Sep; 26(3):337-42. PubMed ID: 6270005
[TBL] [Abstract][Full Text] [Related]
15. Production of human monoclonal antibodies against Epstein-Barr virus-specific antigens by the virus-immortalized lymphoblastoid cell lines.
Koizumi S; Fujiwara S; Kikuta H; Okano M; Imai S; Mizuno F; Osato T
Virology; 1986 Apr; 150(1):161-9. PubMed ID: 3006333
[TBL] [Abstract][Full Text] [Related]
16. Production of monoclonal antibody to a late intracellular Epstein-Barr virus-induced antigen.
Kishishita M; Luka J; Vroman B; Poduslo JF; Pearson GR
Virology; 1984 Mar; 133(2):363-75. PubMed ID: 6324457
[TBL] [Abstract][Full Text] [Related]
17. Relationship between Epstein-Barr virus (EBV)-production and the loss of the EBV receptor/complement receptor complex in a series of sublines derived from the same original Burkitt's lymphoma.
Klein G; Yefenof E; Falk K; Westman A
Int J Cancer; 1978 May; 21(5):552-60. PubMed ID: 207646
[TBL] [Abstract][Full Text] [Related]
18. Antibody-dependent cell-mediated cytotoxicity against Epstein-Barr virus membrane antigen in African Burkitt's lymphoma.
Granlund DJ; Nkrumah F; Perkins IV; Biggar RJ; Levine PH; Fuccillo DA
Int J Cancer; 1979 Nov; 24(5):567-71. PubMed ID: 231015
[TBL] [Abstract][Full Text] [Related]
19. A monoclonal antibody that neutralizes Epstein-Barr virus DNA polymerase activity.
Tsai CH; Williams MV; Glaser R
Intervirology; 1990; 31(2-4):215-22. PubMed ID: 2165046
[TBL] [Abstract][Full Text] [Related]
20. Neutralization of lymphocyte immortalization by different strains of Epstein-Barr virus with a murine monoclonal antibody.
Miller G; Heston L; Hoffman G
Infect Immun; 1982 Sep; 37(3):1028-31. PubMed ID: 6182100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
